Praxis Precision Medicines, Inc.
PRAXNext catalyst
PRAX-562
SCN2A and SCN8A developmental and epileptic encephalopathies
Get an email about PRAX's next catalysts
Track Praxis Precision Medicines (PRAX) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 5 more upcoming events in our data (earnings, Phase 3 readout, PDUFA date).See the timeline
6 upcoming, 0 past
PRAX Earnings Report
EPS Est: $-3.68 | FQ end Sep/2026 | Call: bmo
elsunersen Phase 3 Est. Readout
Estimated primary completion for elsunersen trial (NCT07019922) in Epileptic Encephalopathy. Topline data typically follows completion by weeks to months.
SourcePRAX-562 Phase 3 Est. Readout (EMERALD)
Primary completion for PRAX-562 trial (NCT07010471) in Developmental and Epileptic Encephalopathy 1
SourceFDA PDUFA Date relutrigine (PRAX-562)
For SCN2A and SCN8A developmental and epileptic encephalopathies. NDA; review extended after a major amendment, mid-cycle review completed. Verified against the company announcement on 2026-10-16.
Sourcevormatrogine Phase 3 Est. Readout (POWER2)
Primary completion for vormatrogine trial (NCT07505004) in Focal Epilepsy
SourceFDA PDUFA Date ulixacaltamide (PRAX-944)
For essential tremor. NDA; mid-cycle review completed, no advisory committee planned. Verified against the company announcement on 2026-10-16.
SourceUpcoming FDA decisions
Market Overview
Stock performance and key metrics
PRAX-562
SCN2A Encephalopathy
elsunersen
Epileptic Encephalopathy
vormatrogine
Focal Epilepsy
ulixacaltamide
Essential Tremor
PRAX-628
Focal Seizure
PRAX-114
Major Depressive Disorder
PRAX-222 - Fixed Doses
SCN2A-DEE
PRAX-944
Essential Tremor
PRAX-222 - Optional Ascending Doses
SCN2A-DEE
PRAX-222 - Initial Dose
SCN2A-DEE
to PRAX-944
Essential Tremor
PRAX-222 - Initial Ascending Doses
SCN2A-DEE
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
PRAX-562 | Phase 3 | SCN2A Encephalopathy | - | - |
elsunersen | Phase 3 | Epileptic Encephalopathy | - | - |
vormatrogine | Phase 3 | Focal Epilepsy | - | - |
ulixacaltamide | Phase 3 | Essential Tremor | - | - |
PRAX-628 | Phase 3 | Focal Seizure | - | - |
PRAX-114 | Phase 3 | Major Depressive Disorder | - | - |
PRAX-222 - Fixed Doses | Phase 2 | SCN2A-DEE | - | - |
PRAX-944 | Phase 2 | Essential Tremor | - | - |
PRAX-222 - Optional Ascending Doses | Phase 2 | SCN2A-DEE | - | - |
PRAX-222 - Initial Dose | Phase 2 | SCN2A-DEE | - | - |
to PRAX-944 | Phase 2 | Essential Tremor | - | - |
PRAX-222 - Initial Ascending Doses | Phase 2 | SCN2A-DEE | - | - |
Frequently asked questions
What is in Praxis Precision Medicines, Inc.'s drug pipeline?→
CatalystAlert tracks 12 drug candidates in Praxis Precision Medicines, Inc.'s (PRAX) pipeline across Phase 3, Phase 2. Its lead program is PRAX-562 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Praxis Precision Medicines, Inc.'s next FDA catalyst?→
Praxis Precision Medicines, Inc.'s (PRAX) next tracked catalyst is a PDUFA date expected Dec 27, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track PRAX biotech catalysts?→
Add PRAX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Praxis Precision Medicines, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.